title: H pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium.
abstract: OBJECTIVE
  To investigate whether adding ecabet sodium to the standard triple therapy for H pylori infection improve eradication rate.
  
  
  METHODS
  Two hundred and fifty-seven H pylori-infected patients were randomly assigned to standard triple therapy (group A, n = 129) or triple therapy plus ecabet sodium (group B, n = 128). Successful eradication was defined as a negative (13)C-urea breath test 6-8 wk after completion of treatment.
  
  
  RESULTS
  After completion of therapy, 194/257 patients showed negative (13)C-urea breath test results. According to intention-to-treat analysis, the infection was eradicated in 93/129 (72.1%) patients in group A and 101/128 (78.9%) in group B (P = 0.204). Per-protocol analysis showed successful eradication in 93/118 (78.8%) patients from group A and 101/114 (88.6%) from group B (P = 0.044). There were no significant differences in the side effects experienced by the patients in the two treatment groups.
  
  
  CONCLUSIONS
  Our results suggest that the addition of ecabet sodium improves the efficacy of the standard triple therapy for H pylori.
authors.affiliation: Department of Internal Medicine, Bongseng Memorial Hospital, Busan, Korea.
authors.forename: Hyung Wook
authors.initials: HW
authors.lastname: Kim
authors.forename: Gwang Ha
authors.initials: GH
authors.lastname: Kim
authors.forename: Jong Yun
authors.initials: JY
authors.lastname: Cheong
authors.forename: Ung Suk
authors.initials: US
authors.lastname: Yang
authors.forename: Seung Keun
authors.initials: SK
authors.lastname: Park
authors.forename: Chul Soo
authors.initials: CS
authors.lastname: Song
authors.forename: Dae Hwan
authors.initials: DH
authors.lastname: Kang
authors.forename: Geun Am
authors.initials: GA
authors.lastname: Song
mesh_terms: D045784:Abietanes / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use; D001944:Breath Tests; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D045784:Abietanes; D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; C061681:ecabet